Overview: Islet Cell Antibody TestIntroduction: The Islet Cell Antibody Test detects islet cell antibodies to diagnose autoimmune diabetes, causing high blood sugar or fatigue. Aligned with 2023 ADA guidelines, it uses immunoassay for high specificity, supporting diabetes screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in serology for patients with suspected type 1 diabetes.
Other Names: Islet Cell Ab Assay, Autoimmune Diabetes Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: Islet cell antibody testing began in the 1970s with type 1 diabetes research. Immunoassay-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects islet cell antibodies to diagnose autoimmune diabetes, guides treatment, and evaluates patients with high blood sugar or fatigue.
Test Parameters: 1. Islet Cell Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of high blood sugar, fatigue, or diabetes symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document high blood sugar, fatigue, weight loss, or family history of diabetes. Include current medications, especially insulin.
Consent: Written consent required, detailing the tests purpose, diabetes implications, and risks of blood or saliva collection.
Procedural Considerations: Uses immunoassay to detect islet cell antibodies in serum or saliva. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for type 1 diabetes diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Insufficient sample volume may reduce accuracy.
Clinical Significance: Positive islet cell antibodies confirm type 1 diabetes, guiding insulin therapy. Negative results may require further autoimmune testing.
Specialist Consultation: Consult an endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: GAD65 antibodies, insulin antibodies, or HbA1c to confirm autoimmune diabetes diagnosis.
Test Limitations: Not specific to type 1 diabetes; other autoimmune conditions may produce antibodies. Clinical correlation is needed.
References: ADA Diabetes Guidelines, 2023; Diabetes Care, Atkinson MA, 2022.
